Potential Impact of Accelerating the Primary Dose of Pneumococcal Conjugate Vaccine in Infants

Stancil, Jennifer M.; Peters, Timothy R.; Givner, Laurence B.; Poehling, Katherine A.

doi:10.1001/archpediatrics.2009.39

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2015

Publication Types

Select...

Article4

Relationship

Self Cite1

Independent3

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Similarly, early administration of the pneumococcal conjugate vaccine could prevent approximately 100 cases of invasive pneumococcal disease among young infants in the United States. 25 …”

Section: Discussionmentioning

confidence: 99%

Potential impact of accelerating the primary dose of rotavirus vaccine in infants

Halvorson

Peters

Snively

et al. 2012

Vaccine

Self Cite

View full text Add to dashboard Cite

We estimated the potential impact of administering the first dose of rotavirus vaccine at 6 weeks (42 days of life) instead of 2 months of age, which is permissible for all U.S. vaccines recommended at 2 months of age, on rotavirus hospitalization rates. We used published data for hospitalization rates, vaccine coverage, and vaccine efficacy after one dose and assumed a two-week delay in seroconversion after vaccine administration in the United States. Administering the first dose of rotavirus vaccine at 6 weeks instead of 8 weeks of age should have prevented 1110, 1660, and 2210 rotavirus hospitalizations among U.S. infants <3 months of age in 2006 when the vaccine was first introduced. This estimated benefit represents a 2%-4% reduction in rotavirus hospitalizations among children <5 years of age.

show abstract

Section: Discussionmentioning

confidence: 99%